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Mitochondrial biogenesisEarly onset mitochondrial encephalo-cardiomyopathy due to isolated deﬁciency of ATP synthase is frequently
caused by mutations in TMEM70 gene encoding enzyme-speciﬁc ancillary factor. Diminished ATP synthase
results in low ATP production, elevated mitochondrial membrane potential and increased ROS production.
To test whether the patient cells may react to metabolic disbalance by changes in oxidative phosphorylation
system, we performed a quantitative analysis of respiratory chain complexes and intramitochondrial prote-
ases involved in their turnover. SDS- and BN-PAGE Western blot analysis of ﬁbroblasts from 10 patients
with TMEM70 317-2A>G homozygous mutation showed a signiﬁcant 82–89% decrease of ATP synthase
and 50–162% increase of respiratory chain complex IV and 22–53% increase of complex III. The content of
Lon protease, paraplegin and prohibitins 1 and 2 was not signiﬁcantly changed. Whole genome expression
proﬁling revealed a generalized upregulation of transcriptional activity, but did not show any consistent
changes in mRNA levels of structural subunits, speciﬁc assembly factors of respiratory chain complexes, or
in regulatory genes of mitochondrial biogenesis which would parallel the protein data. The mtDNA content
in patient cells was also not changed. The results indicate involvement of posttranscriptional events in the
adaptive regulation of mitochondrial biogenesis that allows for the compensatory increase of respiratory
chain complexes III and IV in response to deﬁciency of ATP synthase.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Isolated deﬁciency of ATP synthase belongs to autosomally trans-
mitted mitochondrial diseases that typically affect paediatric popula-
tion and present with early onset and often fatal outcome [1].
Nuclear genetic origin of ATP synthase deﬁciency was ﬁrst demon-
strated in 1999 [2] and up to now more than 30 cases have been
diagnosed. Within the last few years, mutations in ATP12 (ATPAF2)
[3] and TMEM70 [4] genes, encoding two ATP synthase ancillary
factors have been identiﬁed as a cause of the disease. Most recently
we have found that a mutation in ATP5E gene coding for ATP synthase
F1 epsilon subunit can also downregulate enzyme biogenesis resulting
in a mitochondrial disease [5]. While ATP12 and ATP5E mutations
remain limited to one unique described case, mutations in TMEM70
were present in numerous patients [4,6–9], thus representing the; ATP synthase, mitochondrial
e c oxidase; RT-PCR, real-time
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rights reserved.most frequent cause of ATP synthase deﬁciency. Up to now at least
8 different pathogenic mutations have been found in TMEM70
gene [4,8–10]; however, most of the patients are homozygous for
TMEM70 317-2A>G mutation thus forming a unique cohort of cases
with an isolated defect of the key enzyme of mitochondrial ATP
production, harboring an identical genetic defect.
TMEM70 is a 21 kDa mitochondrial protein of the inner mitochon-
drial membrane [11] synthesized as a 29 kDa precursor. It functions
as an ancillary factor of mammalian ATP synthase biogenesis [12], and
is uniquely speciﬁc for higher eukaryotes [4,13]. Its absence caused
by the homozygous substitution in TMEM70 gene (317-2A>G) results
in an isolated decrease of the content of fully assembled ATP synthase
and reduction of enzyme activity to less than 30% of control values.
The clinical presentation of affected patients includes the early onset,
lactic acidosis, frequent cardiomyopathy, variable CNS involvement
and 3-methylglutaconic aciduria [1,2,4,14].
Diminished phosphorylating capacity of ATP synthase, with re-
spect to respiratory chain capacity, results in low ATP production
and insufﬁcient discharge of mitochondrial proton gradient. Elevated
levels of mitochondrial membrane potential (ΔΨm) thus stimulate
mitochondrial ROS production and the overall metabolic disbalance
is characterized by insufﬁcient energy provision and increased oxida-
tive stress in ATP synthase-deﬁcient patient cells [1,15].
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mitochondrial signaling, in the present study we tested whether the
patient cells may respond to ATP synthase deﬁciency and consequent
metabolic disbalance by changes in biogenesis of mitochondrial
OXPHOS system. To investigate possible compensatory/adaptive
changes, we performed quantitative analysis of mitochondrial respi-
ratory chain complexes I–V and intramitochondrial proteases (Lon
protease, paraplegin, and prohibitins), quantiﬁed mtDNA content
and compared the protein analysis data with the data from gene ex-
pression proﬁling analyses.
2. Materials and methods
2.1. Patients
Fibroblast cultures from 10 patients with isolated deﬁciency of
ATP synthase (P4–P13 [4]) and 3 controls were used in this study.
All the patients showed major clinical symptoms associated with
ATP synthase deﬁciency and harbored a homozygous substitution
317-2A>G in gene TMEM70 [4]. Relevant clinical, biochemical and
molecular data on individual patients included in this study were
described previously (see [2,4,6,14,16]).
2.2. Cell culture and isolation of mitochondria
Fibroblast cultures were established from skin biopsies and
were grown at 37 °C in 5% (v/v) CO2 atmosphere in high-glucose
Dulbecco's modiﬁed Eagle's medium (DMEM, PAA) supplemented
with 10% (v/v) fetal calf serum. When indicated, cultivation was also
performed in DMEMwithout glucose (Sigma) that was supplemented
with 5.5 mM galactose and 10% dialyzed fetal calf serum. Cells were
harvested with 0.05% trypsin and 0.02% EDTA and washed twice
with phosphate-buffered saline (PBS, 8 g/l NaCl, 0.2 g/l KCl, 1.15 g/l
Na2HPO4, 0.2 g/l KH2PO4). The protein content was measured by Bio-
Rad Protein Assay (Bio-Rad Laboratories), using BSA as standard.
Mitochondria were isolated as in [5] by hypotonic shock cell
disruption [17].
2.3. mtDNA quantiﬁcation
Genomic DNA was isolated by QIAamp DNA Mini kit (Qiagen). To
quantify the mtDNA content, we selected two mitochondrial target
sequences—16S rRNA and D-loop, and GAPDH as a nuclear target. RT-
PCR (LightCycler 480 instrument, Roche Diagnostics) was performed
with SYBR Green Master kit (Roche) using the following primers—16S
(5′ -3′): F-CCAAACCCACTCCACCTTAC, R-TCATCTTTCCCTTGCGGTA; D-
loop: F-CACCATCCTCCGTGAAATCAA, R-GCGAGGAGAGTAGCACTCTTGTG;
GAPDH: F-TTCAACAGCGACACCCACT, R-CCAGCCACTACCAGGAAAT [18].
The mtDNA content was calculated from threshold cycle (CT) ratio
of CTmtDNA/CTnDNA.
2.4. Electrophoresis and immunoblot analysis
Tricine SDS polyacrylamide gel electrophoresis (SDS-PAGE) [19]
was performed on 10% (w/v) polyacrylamide slab minigels (Mini
Protean, Bio-Rad). The samples were incubated for 20 min at 40 °C
in 2% (v/v) mercaptoethanol, 4% (w/v) SDS, 10 mM Tris-HCl (pH
7.0) and 10% (v/v) glycerol. Bis-Tris blue-native electrophoresis
(BN-PAGE) was performed on 4–13% polyacrylamide minigels [20].
Fibroblasts were solubilized by dodecyl maltoside (DDM, 2 g/1 g of
protein) for 15 min at 4 °C in 1.75 mM 6-aminohexanoic acid, 2 mM
EDTA, 75 mM Bis-Tris (pH 7). Samples were centrifuged for 20 min
at 30000 g and 4 °C, Coomassie Brilliant Blue G-250 (8:1, DDM:dye)
and 5% glycerol were added to the supernatants and electrophoresis
was run for 30 min at 45 V and then at 90 V at 4 °C.The separated proteins were blotted onto PVDF membranes
(Immobilon-P, Millipore) by semi-dry electro transfer for 1 h at
0.8 mA/cm2. The membranes were blocked with 5% (w/v) non-fat
milk in TBS, 0.1% (v/v) Tween-20 and then incubated for 2 h or overnight
with subunit speciﬁc antibodies. We used monoclonal antibodies from
Mitosciences against complex I (NDUFA9-MS111, NDUFS3-MS112),
complex II (SDH70-MS204), complex III (Core1-MS303, Core2-MS304),
complex IV (Cox1-MS404, Cox2-MS405, Cox4-MS408, Cox5a-MS409),
complex V-ATP synthase (F1-β-MS503), and against porin (MSA03).
For detection of proteases, the polyclonal antibodies to Lon (kindly pro-
vided by Dr. E. Kutejova), paraplegin (kindly provided by Dr. T. Langer),
prohibitin 1 (Lab Vision/NeoMarkers) and prohibitin 2 (Bethyl, A300-
657A) were used. Quantitative detection was performed using infrared
IRDye®-labeled secondary antibodies (goat anti-mouse IgG, Alexa Fluor
680 (A21058) and goat anti-rabbit IgG, Alexa Fluor 680 (A21109),
Invitrogen) and Odyssey Infrared Imager (Li-Cor); the signal was quan-
tiﬁed by AIDA 3.21 Image Analyzer software (Raytest).2.5. Gene expression analysis
RNA isolations and RNA quality control were performed as previ-
ously described [4]. Total RNA (500 ng) was reverse transcribed,
labeled and hybridized onto Agilent 44 k human genome microarray
using Two-color Microarray Based Gene Expression Analysis Kit
(Agilent). Patient samples and controls (Cy5-labeled)were hybridized
against common Cy3-labeled reference RNA isolated from HeLa cell
lines. The hybridized slides were scanned with Agilent scanner with
PMT gains adjusted to obtain highest intensity unsaturated images.
Gene PixPro software (Axon Instruments) was used for image analysis
of the TIFF ﬁles generated by the scanner. Comparative microarray
analysis was performed according to MIAME guidelines [21]. Normal-
ization was performed in R statistic environment (http://www.r-
project.org) using Limma package [22], a part of Bioconductor project
(http://www.bioconductor.org). Raw data from individual arrays
were analyzed as one color data and processed using loess normaliza-
tion and normexp background correction. Quantile was used for
normalization between arrays. Linear model was ﬁtted for each gene
given a series of arrays using lmFit function. The empirical Bayes
methodwas used to rank differential expression of genes using eBayes
function. Multiple testing correctionwas performed using themethod
of Benjamini and Hochberg [23].2.6. Data accession
Expression data reported in this study are stored and available in
Gene Expression Omnibus repository under accessions GPL4133 and
GSE10956.2.7. Protein/transcript correlation
Gene expression signals were background corrected, log2 trans-
formed and normalized using the quantile normalization method.
Relative protein levels (ratio to porin) were mean centered, averaged
and log2 transformed. For all possible pairs of genes and proteins, we
calculated the Pearson correlation coefﬁcient and its signiﬁcance
levels using correlation test function in R statistical language.2.8. Ethics
This study was carried out in accordance with the Declaration of
Helsinki of the World Medical Association and was approved by the
Committees of Medical Ethics at both collaborating institutions. The
informed consent was obtained from parents.
Table 1
Protein content of OXPHOS subunits (A), OXPHOS complexes (B) and mitochondrial pro-
teases (C) in ﬁbroblasts of patients with TMEM70mutation expressed in % of control. Data
are mean±SD and p-values are determined by t-test (p-values b0.05 are in bold).
A
Complex Subunit % control±SD p-value
ATP synthase F1β 18±5.5 9.4121E−08
Complex I NDUFA9 115±29.2 0.4623
Complex I NDUFS3 110±35.2 0.7369
Complex II SDH70 125±28.1 0.2747
Complex III Core 1 133±20.2 0.0309
Complex III Core 2 124±16.6 0.0477
Complex IV Cox1 150±21.1 0.0084
Complex IV Cox2 262±74.0 0.0052
Complex IV Cox4 107±30.0 0.7243
Complex IV Cox5a 163±21.6 0.0003
B
Complex Antibody to % control±SD p-value
ATP synthase F1β 11±4.8 0.0001
Complex I NDUFA9 126±54.4 0.3150
Complex II SDH70 101±14.9 0.9799
Complex III Core 1 153±70.6 0.0463
Complex IV Cox1 184±83.6 0.0207
C
Protein % control±SD p-value
Lon protease 136±61 0.4516
Paraplegin 104±27.6 0.9793
Prohibitin 1 99±36.1 0.2763
Prohibitin 2 90±10.7 0.8514
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3.1. Changes in the content of mitochondrial OXPHOS complexes and
mtDNA
To analyze possible changes in mitochondrial OXPHOS system, we
determined by SDS-PAGE andWestern blotting the protein content of
individual OXPHOS complexes in homogenates of ﬁbroblasts from 10
patients with ATP synthase deﬁciency caused by TMEM70 mutation
and from 3 healthy controls. We used monoclonal antibodies to
selected subunits of ATP synthase (subunit β), complex I (NDUFA9,
NDUFS3), complex II (SDH70), complex III (Core1, Core2) and com-
plex IV (Cox1, Cox2, Cox4, and Cox5a). The signal of each subunit
was normalized to the signal of porin and expressed as percentage
of controls. As shown in Fig. 1, the average content of ATP synthase
decreased to 18% of the controls. In contrast, the content of respirato-
ry chain complexes I, II, III, and IV accounted for 115%, 125%, 133%,
and 163% of the controls, using antibodies to NDUFA9, SDH70,
Core1, and Cox5a, respectively. Analogous differences were observed
when the immunodetection data were calculated per mg of protein
(102%, 123%, 150%, and 170% of the controls). A similar pattern of
changes was found when using antibodies to other subunits of
these complexes (Table 1A). The calculation from each subunit signal
data thus revealed a signiﬁcant increase to 124–133% of the control in
complex III subunits and to 150–262% in complex IV subunits. Only
detection of the subunit Cox4 behaved differently than other complex
IV subunits, and the change of its content was small and insigniﬁcant.
The changes in complex IV and complex III content revealed
by SDS-PAGE were also observed at the level of assembled OXPHOS
complexes resolved by BN-PAGE of DDM-solubilized mitochondrial
proteins (Fig. 2, Table 1B). Cytochrome c oxidase detected with
Cox1 antibody was increased to 184% of the control. The bc1 complex
detected with Core 1 antibody was increased to 153% of the control.
There was also a tendency of increase in the complex I content but
the difference was not signiﬁcant due to a large variation of values.
The content of complex II that accounted for 101% of the control
was the least varying one. When the relative ratio of complexes III,
IV and V to complex II was calculated and compared to control,
the complex V was decreased to 11% and complexes III and IV were
increased to 130% and 181%, respectively.
We have also performed cultivation of ﬁbroblasts in galactose
medium lacking glucose to increase their dependence on oxidative me-
tabolism. As a result, the growth of patient ﬁbroblasts with TMEM70
mutation progressively declined and after 2–3 passages they stopped
growing. SDS-PAGE andWestern blotting did not reveal any signiﬁcant
change in respiratory chain complexes I–IV, due to the change in
cultivation conditions, there was also no change in the low content of
complex V (not shown).Fig. 1. The protein content of respiratory chain complexes in ﬁbroblasts with TMEM70
subunit speciﬁc monoclonal antibodies. Detected signals were normalized to mitochondri
line. B—Statistical analysis of 10 patient cell lines, box plot represents maximum, Q3, mediaWhen determining the content of mtDNA in patient and control
ﬁbroblasts, we found that the mtDNA copy number reﬂected by
mtDNA/nDNA ratio is not inﬂuenced by the TMEM70 mutation
(Table 2).
3.2. Changes in mitochondrial proteases
When the ATP synthase assembly is impaired due to TMEM70
mutation, the unused subunits of ATP synthase have to be degraded
by mitochondrial quality control system [24]. Therefore, we analyzed
the protein content of several components of mitochondrial proteo-
lytic machinery in ﬁbroblast mitochondria by Western blotting
using polyclonal antibodies to matrix Lon protease that degrades
misfolded, unassembled and oxidatively damaged matrix proteins
[25], paraplegin, subunit of the inner membrane mAAA protease that
degrades membrane spanning and membrane associated subunits of
respiratory chain complexes [26] and prohibitins 1 and 2—regulatory
proteins of AAA proteases [27]. As shown in Fig. 3, the changes in themutation. SDS-PAGE and Western blot analysis of ﬁbroblasts were performed using
al marker porin and expressed in % of control values. A—Values for each patient cell
n, Q1, and minimum.
Fig. 2. The content of native respiratory chain complexes in ﬁbroblasts with TMEM70mutation. BN-PAGE and Western blot analysis of DDM-solubilized ﬁbroblasts were performed
using subunit speciﬁc monoclonal antibodies. A—Analysis of control and P13 patient ﬁbroblasts is shown. Detected signals were expressed in % of control values. B—Values for each
patient cell line. C—Statistical analysis of 10 patient cell lines, box plot represents maximum, Q3, median, Q1, and minimum.
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did not reveal signiﬁcant differences in patient cells as compared
with the controls. In case of Lon proteasewe observed only amoderate
increase of about 30%; however, this difference was also not statisti-
cally signiﬁcant.
3.3. Changes in mRNA expression proﬁles
To assess putative changes in transcriptional activity of genes
involved in mitochondrial biogenesis, we analyzed mRNA expression
proﬁles using whole genome (44 k) array. From the whole dataset,
51% gene spots provided a signal of sufﬁcient quality to be used
for microarray analysis. Out of this subset, there were 2700 genes
upregulated and 525 downregulated in patient cells as compared to
controls at unadjusted pb0.05. At adjusted pb0.01, 104 and 2 genes
were upregulated and downregulated, respectively.
The generalized upregulation of transcriptional activity in patient
cells indicates their tendency to increase the levels of majority
of transcripts. However, only a small number of the signiﬁcantly
upregulated genes were associated with OXPHOSmetabolism. No sig-
niﬁcant differences in expression levels of the genes encoding ATP
synthase subunits and ATP synthase assembly factors were found;
the only exception was TMEM70 gene whose transcript in patient
cells was decreased by a factor of 4.6 (adj. pb0.001). Furthermore,
in case of other genes encoding OXPHOS subunits only the expression
of 6 genes differed from the controls (unadjusted pb0.05, Table 3).
Speciﬁcally, 3 subunits of complex I, 1 subunit of complex II, and 2
subunits of complex III, revealed slight (1.2–1.6 fold change) but
non-consistent changes, with up- and downregulation observed for
genes encoding different subunits of the same complex.
Among differentially expressed genes two pro-mitochondrial
regulatory genes, the TFAM and PPRC1 participating in mitochondrial
biogenesis were 1.3 fold upregulated, while the COX-speciﬁc SCO2
assembly factor was downregulated. The expression proﬁling did not
reveal any changes in mitochondrial proteases or other components
of the mitochondrial quality control system.
3.4. Correlation of expression proﬁling and protein amount
In the investigated group of OXPHOS genes (structural subunits
or speciﬁc assembly factors) we did not ﬁnd any correlation betweenTable 2
The content of mtDNA in patient ﬁbroblasts, determined as a ratio between mtDNA
(16S or D-loop) and nDNA (GAPDH), expressed in % of control.
mtDNA gene/nDNA gene % control±SD
16S/GAPDH 100.21±1.41
D-loop/GAPDH 101.00±1.95mRNA and protein levels. Even in case of complexes IV and III, with
signiﬁcantly increased protein content, no parallel signiﬁcant changes
in mRNA levels were found in corresponding nuclear or mtDNA
encoded genes. The results indicate that ATP synthase deﬁciency-
induced changes in respiratory chain complexes are not related
with corresponding changes in the transcriptional activity of the
genes involved in OXPHOS biogenetic machinery.
4. Discussion
The aim of our study was to investigate possible compensatory/
adaptive changes of mitochondrial OXPHOS system in a unique
group of ﬁbroblast cell lines from 10 patients with an identical muta-
tion in TMEM70 gene, downregulating speciﬁcally the ATP synthase
(complex V) content and function. We found a pronounced and
signiﬁcant increase in cellular protein content of the subunits of
respiratory chain complex III and complex IV, in accordance with
our previous analysis of one of the patients [16]. The increase of
complex IV subunits was found in mtDNA encoded subunits Cox1
and Cox2 and in nuclear encoded subunit Cox5a, ranging 150–262%
of the control, whereas Cox4 protein showed only a small increase.
Complex III was increased in Core1 and Core2 subunits and accounted
for 125–133% of the control. BN-PAGE analyses further showed that
these changes reﬂected a corresponding increase to 153% and 184%
in assembled respiratory complexes III and IV, respectively.
Changes in the content, morphology, or cellular localization of
mitochondria, as well as secondary changes in the content of some
of mitochondrial OXPHOS complexes are often observed in mitochon-
drial disorders. Good examples are ragged-red muscle ﬁbers of
MERRF patients with mtDNA 8344A>G mutation in the tRNALys
gene [28], mitochondrial cardiomyopathies [29] or AZT-induced
mtDNA depletion [30]. However, little is known about the underlying
adaptive mechanisms.
The pronounced isolated defect in one OXPHOS complex in-
duced by identical homozygous autosomal mutation, such as ATP
synthase deﬁciency studied here, represents an interesting model
for investigation of possible adaptive changes. Despite methodical
limitations of patient cell culture studies (differences in patients'
age, number of passages in cell culture), the upregulation of
complex IV and complex III could be demonstrated as an apparent
consequence of complex V deﬁciency in patients with TMEM70
317-2A>G homozygous mutation [4], leading to the absence
of the TMEM70 protein [11]. Interestingly, when we analyzed
ﬁbroblasts with ATP synthase deﬁciency due to mutation in ATP5E
gene, we also observed elevated contents of complexes III and IV
[5]. On the other hand, in case of ATP synthase deﬁciency due to
ATP12 mutation, BN-PAGE and in gel enzyme activity staining
revealed unchanged content of respiratory chain complexes I, II
and IV [3]. However, for each of these two mutations (ATP5E,
Fig. 3. The protein content of mitochondrial proteases in ﬁbroblasts with TMEM70 mutation. The content of Lon protease, paraplegin subunit of mAAA protease, prohibitin 1 and
prohibitin 2 was analyzed in ﬁbroblasts mitochondria by SDS-PAGE and WB using polyclonal antibodies. Detected signals in patient ﬁbroblasts were normalized to protein content
and expressed in % of controls. A—Values for each patient cell line. B—Statistical analysis of 10 patient cell lines, box plot represents maximum, Q3, median, Q1 and minimum.
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these observations can hardly be generalized.
Mitochondrial OXPHOS complexes are formed independently by
biogenetic processes with the help of numerous, complex-speciﬁc
helper proteins [31,32]. The decreased content of ATP synthase
could therefore inﬂuence biogenesis and assembly of other respirato-
ry complexes only indirectly, possibly via changes in membrane
potential (ΔΨm), adenine nucleotides levels or mitochondrial ROS
production [1,15]. High values of ΔΨm, increased ROS production as
well as low ATP production are also hallmarks of ATP synthase dys-
function due to mtDNA mutations in ATP6 gene encoding subunit a
of ATP synthase. The most pathogenic is T8993G missense mutation
resulting in numerous NARP/MILS cases at high mutation load
[33,34]. Pathogenic mechanism of T8993G mutation has been inten-
sively studied in different tissues, ﬁbroblasts and derived cybrids
and while some authors observed increase of the respiratory chain
complexes [35], others found no signiﬁcant changes [36] or even
decrease [34]. It is possible that this variability may reﬂect varying
heteroplasmy of ATP6 mutation; however, a nuclear genetic back-
ground of different patients should also be considered [37]. Our data
also showed a pronounced variation of the adaptive responses at
the level of complex IV and complex III in individual cell lines with
homozygous TMEM70 mutation, which may reﬂect differences in
nuclear genome of individual cases, determining their potential to
respond to underlying ATP synthase deﬁciency.
The extent of adaptive response could depend on the relative con-
tribution of OXPHOS system to the overall energetics of ﬁbroblasts,
which is small as ﬁbroblasts are largely glycolytic cells. However,
we were not able to further increase upregulation of respiratory
chain complexes in ﬁbroblasts with TMEM70 mutation by cultivating
them in galactose medium in order to increase their oxidative metab-
olism. In fact, the viability of ﬁbroblasts with TMEM70 mutation was
strongly impaired and they stopped growing in galactose medium.Table 3
OXPHOS genes expressed differently in patient and control cells (unadjusted pb0.05).
Gene ID Gene Gene name
NM_004548 NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta
NM_005006 NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S p
NM_015965 NDUFA13 NADH dehydrogenase (ubiquinone) 1 alph
NR_003266 LOC220729 Succinate dehydrogenase complex, subunit
NM_001003684 UCRC10 Ubiquinol-cytochrome c reductase, comple
NM_003366 UQCRC2 Ubiquinol-cytochrome c reductase core pro
NM_005138 SCO2 SCO cytochrome oxidase deﬁcient homolog
NM_017866 TMEM70 Transmembrane protein 70
NM_015062 PPRC1 Peroxisome proliferator-activated receptor
NM_003201 TFAM Transcription factor A, mitochondrialThis would indicate that the lack of ATP synthase prevents sufﬁcient
ATP production when glycolysis was inhibited and that observed
compensatory upregulation of respiratory chain complexes was, as
expected, energetically unproductive.
It would be interesting to see whether the variation of data in
ﬁbroblast cell lines associates with the in vivo impairment of mito-
chondrial energetics and consequently with the clinical state of indi-
vidual cases. Nevertheless, it is very problematic to link the changes
in respiratory chain complexes in ﬁbroblasts with the clinical presen-
tation of TMEM70 mutation as previous clinical studies of large
number of patients revealed no real differences in the disease onset
and severity of clinical symptoms and indicated that management
of intensive care after the birth is crucial for patients' survival beyond
the neonatal period [6].
Studies in yeast represent efﬁcient strategy to investigate patho-
genic mechanisms of human mitochondrial diseases, in particular
various types of ATP synthase disorders [38]. Di Rago and colleagues
created a yeast model of ATP6 mutations and recent studies in
Saccharomyces cerevisiae demonstrated both in ATP synthase-
deﬁcient or in oligomycin-inhibited cells that the content of complex
IV selectively and rapidly decreases, due possibly to translational
downregulation of Cox1 subunit caused by high ΔΨm [39]. This is
in sharp contrast with upregulation of complex IV in patient cells
with TMEM70 mutation. Apparently, the yeast and mammalian/
human cells respond differently to dysfunction of ATP synthase
and consequent increase of ΔΨm, due to differences in the mecha-
nism and regulation of synthesis and assembly of mtDNA encoded
Cox1. While Cox1 is synthesized in a precursor form in S. cerevisiae
and its translation and processing depend on MSS51 [40], human
Cox1 is not processed and its translation is controlled by two factors,
TACO1, a speciﬁc translational activator that might have evolved
in concert with the loss of the mitochondrial mRNA regulatory
sequences that occurred with the extreme reduction in the size ofM Fold change p-value
subcomplex, 10, 22 kDa −0.32 1.3 0.051
rotein 1, 75 kDa 0.28 1.2 0.039
a subcomplex, 13 −0.31 1.2 0.046
A 0.64 1.6 0.001
x III subunit X −0.45 1.4 0.012
tein II 0.34 1.3 0.025
2 (yeast) −0.26 1.2 0.042
−2.20 4.6 b0.001
gamma, coactivator-related 1 0.38 1.3 0.005
0.39 1.3 0.007
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speciﬁc, small transmembrane protein that is required for coordina-
tion of the Cox1 synthesis with the early steps of COX assembly [42].
The important ﬁnding of our study is that the observed adaptive
response of mitochondrial biogenesis is probably enabled by post-
transcriptional events that allow for an increased biosynthesis of
two respiratory chain complexes without correspondingly increased
mRNAs. Our attempts to link protein changes to transcriptional pro-
ﬁles did not show any direct correlation. Besides very low TMEM70
transcript, only 9 genes encoding OXPHOS biogenesis proteins were
differentially expressed, but only with a low signiﬁcance, including
two pro-mitochondrial regulatory genes participating in mitochon-
drial biogenesis, viz TFAM and PPRC1 (PGC-1 related co-activator)
that were 1.3-fold increased. As neither the mRNAs for multiple
regulatory and/or assembly factors, nor for structural subunits of
complexes III and IV were consistently increased, our data suggest
that posttranscriptional, possibly translational regulation may be re-
sponsible for the adaptive changes observed. It is tempting to specu-
late that ΔΨm and/or ROS may be the signals activating/stimulating
this process and that the targets might be the factors such as the tran-
scriptional activator TACO1 [41], metazoan speciﬁc LRPPRC protein
implicated in regulation of stability and handling of maturemitochon-
drial mRNAs as part of a ribonucleoprotein complex [43], processing
of ribosomal MRPL32 protein by mAAA protease [44] or alike, and
that the observed adaptive responses may include increased stability
of the mRNA coding for some subunits of upregulated OXPHOS
complexes, or a longer half-life of the corresponding protein subunits,
or both.
The pronounced isolated deﬁciency of one key complex of mito-
chondrial energy provision also represents an interesting model to
study the function of mitochondrial biogenesis quality control system
that determines the fate of all newly synthesized mitochondrial
proteins and directly modulates mitochondrial translation [24,45].
Our analysis of mitochondrial proteases revealed that the elimination
of unassembled subunits of ATP synthase is associated neither with
the increased mitochondrial content of these proteases nor with
upregulation of the respective transcripts. The degradation of excess
subunits can be apparently maintained by a normal, steady state
level of mitochondrial proteases. A moderate increase was only
found in case of Lon protease.
Normal levels of transcripts for ATP synthase subunits observed
in patient cells indicate that enzyme subunits are synthesized,
whereas Western blot analysis showed that the unused subunits
are effectively degraded by mitochondrial surveillance system. ATP
synthase is one of the most abundant proteins of mammalian mito-
chondria and represents several percents of the total mitochondrial
protein. However, based on analysis of mitochondrial proteases as
well as expression proﬁling data, it appears that the capacity of
mitochondrial quality control system is fully sufﬁcient to degrade
the orphan subunits of ATP synthase in cells with TMEM70 muta-
tion, which has been demonstrated by rapid degradation of newly
synthesized beta F1 subunit observed in patient ﬁbroblasts [2].
This is in accordance with the view that up to 30% of newly synthe-
sized nascent mitochondrial proteins are rapidly degraded owing
to folding errors [46,47]. Efﬁcient removal of excess subunits was
also described in complex I disorder due to ND1 mutation [48], or
in SDH deﬁciency in yeasts caused by the lack of SDH5 ancillary
factor [49]. The efﬁcacy of mitochondrial quality control and
protein degradation pathway is also apparent from tissue speciﬁc
downregulation of ATP synthase in brown fat, where the lack of
the subunit c leads to a 10-fold decrease of ATP synthase complex
without any accumulation of unassembled subunits, despite the
fact that their mRNA levels are the highest among mitochondria-
rich mammalian tissues [50]. Under conditions of high excess of
unfolded proteins degraded to peptides, increase in the transcription
of HSP60 or mtHSP70 can be triggered by upregulation of bZIPtranscription factor ZC376.7 [51,52]. However, based on our expres-
sion proﬁling data, this does not seem to be the case in patient cells
with TMEM70mutation.
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